Ozempic (semaglutide injection) is FDA-approved for type 2 diabetes, cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease, and chronic kidney disease risk reduction. More than 80% of the top 10 commercial plans cover Ozempic, and approximately 69% require prior authorization, according to 2026 formulary data from PrescriberPoint. Approval timelines range from 3 to 15 business days depending on the insurer, and incomplete documentation is the single most common reason for denial.
This checklist is for prescribers, benefit verification specialists, hub-services teams, and prior authorization coordinators who need to submit, track, and appeal Ozempic PA requests. It is not medical advice or reimbursement guidance for a specific patient or plan.
Quick answer
| Step | Action | Typical Requirement |
|---|---|---|
| 1 | Confirm diagnosis | Type 2 diabetes mellitus (ICD-10: E11.x) |
| 2 | Document prior therapy | ≥3 months metformin (or contraindication/intolerance documentation) |
| 3 | Obtain current labs | A1C within 6 months; eGFR if relevant |
| 4 | Verify formulary status | Check plan-specific formulary for tier and specialty pharmacy |
| 5 | Complete PA form | Use payer-specific form; include all supporting documentation |
| 6 | Submit and track | Submit electronically where possible; follow up at 5 business days |
| 7 | Appeal if denied | Peer-to-peer review; supplement with additional clinical evidence |
Source standard
Every fact in this checklist is sourced from payer policy documents, PA form requirements, CMS guidance, and trade reporting dated 2025–2026. Coverage rules change frequently. Always verify current-year formulary and PA criteria on the specific plan's member portal or provider portal before submitting.
Required documentation checklist
Diagnosis confirmation
- Documented type 2 diabetes mellitus diagnosis
- ICD-10 code: E11.x series (e.g., E11.9 — type 2 diabetes mellitus without complications; E11.65 — with hyperglycemia)
- Chart notes confirming diagnosis date and duration
- For CKD indication: documented chronic kidney disease with albuminuria (use additional N08.x codes)
- For CV indication: documented established cardiovascular disease (e.g., I25.10 — atherosclerotic heart disease)
Prior therapy documentation
Most payers require a documented trial of at least one first-line oral antidiabetic before approving a GLP-1 receptor agonist:
- Drug name, dose, and frequency of prior therapy (typically metformin)
- Duration of trial — most plans require ≥3 months at maximally tolerated dose
- Reason for discontinuation: inadequate glycemic control (A1C above target), side effects, or contraindication
- If metformin is contraindicated: documented reason (e.g., renal impairment, GI intolerance, vitamin B12 deficiency)
- If additional oral agents were tried: sulfonylurea, SGLT2 inhibitor, or DPP-4 inhibitor with dates and outcomes
Current clinical data
- Most recent A1C result (within 6 months) with date
- Target A1C as established by the treating provider
- Fasting glucose or CGM summary if available
- eGFR result (relevant for CKD indication and metformin eligibility)
- BMI documentation (required by some plans even for diabetes indication)
- Blood pressure reading (relevant for cardiovascular risk reduction indication)
- Liver function tests if relevant
Prescriber and patient information
- Prescriber name, NPI, and specialty
- Patient demographics, insurance ID, group number, and BIN/PCN
- Requested drug: Ozempic (semaglutide injection)
- Requested dose: 0.25 mg, 0.5 mg, 1 mg, or 2 mg (matching titration schedule)
- Quantity and days supply (typically 1 pen per 28–30 days)
- Clinical narrative: why Ozempic is medically necessary for this patient
Payer-specific prior authorization criteria
Aetna (CVS Health)
Aetna manages pharmacy benefits through CVS Caremark. As of 2026 plan year:
- Formulary tier: Preferred Brand / Tier 2–3 on most commercial plans for diabetes indication
- PA required: Yes for most plans
- Step therapy: Metformin trial required before GLP-1 approval
- Key criteria: Documented T2D diagnosis; inadequate glycemic control on prior therapy; A1C documentation
- Approval duration: Typically 12 months
- Specialty pharmacy: CVS Specialty preferred
- Submission: Aetna provider portal or CVS Caremark electronic PA
Aetna accepts prior drug use within the past 365 days as meeting step therapy requirements, even if the trial occurred with a different insurer.
Blue Cross Blue Shield (varies by affiliate)
BCBS coverage varies significantly by state affiliate and plan:
- Formulary tier: Specialty tier (Tier 3–4) on most plans
- PA required: Frequently required
- Step therapy: Common — metformin and sometimes a second oral agent
- Key criteria: T2D diagnosis; documented failure of first-line therapy; A1C above target
- Approval duration: Varies by affiliate; typically 6–12 months
- Notable: Each state BCBS affiliate sets its own formulary and PA criteria. Coverage decisions for the same drug can differ across BCBS plans within the same state
- Submission: Plan-specific PA form; check the member's BCBS affiliate website
Cigna (Evernorth)
- Formulary tier: Preferred Brand (Tier 2) on Performance formulary
- PA required: Yes
- Step therapy: Metformin first; some plans require trial of a second oral agent
- Key criteria: T2D diagnosis; A1C documentation; prior therapy failure
- Approval duration: 6–12 months depending on plan
- Specialty pharmacy: Cigna Specialty or Accredo
- Submission: Cigna provider portal or fax
CVS Caremark
- Formulary position: Ozempic generally covered on commercial formularies for T2D
- PA required: Yes for most plans
- Key criteria: T2D diagnosis; prior oral therapy failure
- Quantity limits: 1 pen per 28 days; refill window applies
- Submission: CVS Caremark PA portal or standard PA form
- Notable: Caremark removed Zepbound from standard commercial formulary effective July 2025, making Wegovy the preferred anti-obesity GLP-1. This formulary shift does not directly affect Ozempic's T2D coverage but signals increased payer scrutiny of the GLP-1 class
UnitedHealthcare
UnitedHealthcare's Ozempic coverage for Virginia (representative of UHC commercial policy):
- Formulary tier: Tier 2–3 (varies by plan)
- PA required: Yes
- Step therapy: Not typically required for T2D indication (per UHC 2025 GLP-1 criteria)
- Key criteria: T2D diagnosis (ICD-10 E11.x); chart notes documenting diabetes management; A1C results from past 6 months
- Approval period: 12 months
- Submission: UHC provider portal
- Processing time: Up to 15 business days standard; 72-hour expedited review available if provider certifies medical urgency
Required documents for UHC submission:
| Document | What to Include | Source |
|---|---|---|
| PA form | Complete UHC GLP-1 PA form | UHC provider portal |
| Medical records | Chart notes documenting T2D diagnosis | Provider office |
| ICD-10 code | E11.x code for type 2 diabetes | Medical billing |
| A1C results | Lab results from past 6 months | Lab portal or provider |
Medicare Part D
Medicare Part D covers GLP-1 drugs for FDA-approved T2D and cardiovascular indications, but a statutory exclusion bars coverage for weight loss alone:
- Covered indications: Type 2 diabetes; cardiovascular risk reduction (Wegovy only, not Ozempic); chronic kidney disease
- Not covered: Weight loss, obesity treatment
- PA required: Yes, for most Part D plans
- Key criteria: Documented T2D diagnosis; prior therapy; A1C above target
- Formulary: At least two drugs per therapeutic category required; not all plans include every GLP-1
- Notable: The CMS Medicare GLP-1 Bridge demonstration starts July 1, 2026, providing access to certain GLP-1 drugs for $50/month through December 31, 2027, but operates outside the Part D benefit and applies to weight-loss indications only
- Source: CMS.gov Medicare GLP-1 Bridge page; Congressional Research Service report IF12758
Medicaid (state-by-state)
Medicaid GLP-1 coverage varies by state. As of 2026:
- T2D indication: Generally covered across states with PA
- Weight-loss indication: Many states have restricted or eliminated GLP-1 coverage for weight loss starting in 2026
- Pennsylvania example: PA Medicaid requires step therapy through semaglutide before approving tirzepatide products; requires documented trial and failure of at least one oral antidiabetic; therapeutic failure defined as failure to achieve positive clinical response
- Key criteria: T2D diagnosis; prior therapy documentation; A1C results; BMI documentation for some states
- Submission: State-specific Medicaid PA forms
- Notable: Medi-Cal excluded GLP-1s for weight loss effective January 1, 2026, but retained Wegovy for MASH and cardiovascular indications
Common denial reasons and how to address them
1. Missing or incomplete prior therapy documentation
What happens: Plan denies because prior metformin trial is not documented with sufficient detail.
Fix: Include drug name, dose, duration (≥3 months), and reason for discontinuation in the clinical narrative. If the patient was on metformin with a different insurer, include the dates and document the therapy history from medical records.
2. Diagnosis code mismatch
What happens: ICD-10 code does not match the approved indication (e.g., coding obesity E66.x instead of T2D E11.x).
Fix: Use E11.x series codes for the primary T2D diagnosis. If requesting Ozempic for CV risk reduction, include both the T2D code (E11.x) and the CVD code (e.g., I25.10).
3. A1C not documented or too old
What happens: Plan denies because A1C result is missing or older than 6 months.
Fix: Order a current A1C before submitting the PA. Include the lab result with date, value, and the provider's target A1C in the clinical notes.
4. Step therapy not met
What happens: Plan requires documented failure of metformin (or another preferred drug) before approving a GLP-1.
Fix: Document the trial period with specific dates, doses, and outcomes. If metformin is contraindicated, provide the clinical reason (e.g., eGFR below 30 mL/min, documented GI intolerance requiring discontinuation).
5. Off-label use request
What happens: Ozempic is requested for an indication not on the FDA label (e.g., weight loss without T2D diagnosis).
Fix: For Medicare: this is a statutory exclusion for weight loss. For commercial plans: some plans cover GLP-1s for weight management with BMI criteria, but typically require Wegovy or Zepbound (the weight-loss branded products) rather than Ozempic. If the patient has both T2D and obesity, code for the T2D diagnosis as the primary indication.
PA submission timeline
| Step | Typical Timeline | Action |
|---|---|---|
| Eligibility and formulary check | Day 0 | Verify plan formulary, PA requirements, specialty pharmacy |
| Gather clinical documentation | Days 0–2 | Collect A1C, prior therapy records, chart notes |
| Complete PA form | Day 2 | Use payer-specific form; attach all documentation |
| Submit PA | Day 2–3 | Electronic submission preferred; fax as backup |
| Payer review | Days 3–15 | Standard: 3–15 business days; expedited: 72 hours |
| Follow up if no response | Day 7 | Contact payer for status update |
| Approval or denial | Day 5–15 | If approved: send Rx to specialty pharmacy. If denied: initiate appeal |
| Appeal (if needed) | Within denial window | Peer-to-peer review; supplement documentation |
Reauthorization
Most plans approve Ozempic for 6–12 months and require reauthorization for continued therapy:
- Document positive clinical response to Ozempic (A1C improvement, weight loss, or other relevant metric)
- Confirm current dose and titration status
- Verify continued medical necessity
- Submit reauthorization request before the current approval expires (allow 2–4 weeks)
- Some plans require documentation of ≥4% weight loss or A1C improvement for GLP-1 reauthorization
Patient assistance and copay support
If PA is denied or the patient faces high copay costs:
- Ozempic Savings Program (covered benefit): Novo Nordisk offers a copay card that reduces the out-of-pocket cost to as low as $25/month for eligible commercially insured patients. Check current terms at the Novo Nordisk patient assistance website
- Ozempic Savings Program (non-covered benefit): For patients whose insurance does not cover Ozempic, Novo Nordisk offers a separate cash-pay assistance program
- Patient Assistance Program (PAP): Novo Nordisk provides free medication to eligible uninsured or underinsured patients who meet income criteria
What changed recently
- 2025–2026 GLP-1 formulary shifts: CVS Caremark made Wegovy the preferred anti-obesity GLP-1 and removed Zepbound from standard formularies (July 2025). Other PBMs have implemented similar formulary strategies. These shifts affect how plans view the GLP-1 class overall but do not directly change Ozempic's T2D coverage
- Medicare GLP-1 Bridge: Starting July 1, 2026, CMS will provide eligible Part D beneficiaries access to certain GLP-1 drugs for $50/month through December 31, 2027. This demonstration operates outside the Part D benefit and targets weight-loss indications
- Ozempic 2 mg dose: The FDA approved the 2 mg weekly dose of Ozempic, expanding the dose range. Some plans may require documentation of titration from lower doses before approving the 2 mg strength
- Expanded CKD indication: Ozempic received FDA approval for reducing the risk of kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. This indication may support PA submissions that include CKD documentation
What to monitor next
- Medicare GLP-1 Bridge implementation details: CMS has not yet published the full list of eligible GLP-1 drugs or the PA criteria for the Bridge demonstration. Monitor CMS.gov for updates before the July 1, 2026, launch
- State Medicaid GLP-1 policy changes: Multiple states are reassessing GLP-1 coverage for 2026. Monitor state Medicaid agency websites and the Federal Register for policy updates
- Ozempic generic entry timeline: Semaglutide is under patent protection. Monitor Orange Book listings and generic manufacturer ANDA filing dates for early signals of when generic competition may arrive
- Oral semaglutide expansion: Rybelsus (oral semaglutide) is available in higher doses. If a once-daily oral formulation expands, it may shift payer step-therapy hierarchies
- IRA negotiation implications: If semaglutide is selected for Medicare negotiation in a future cycle, the negotiated price could affect formulary positioning and PA stringency across Part D plans
Sources
- PrescriberPoint. Ozempic Savings Card, Coupon & Coverage 2026. https://prescriberpoint.com/therapies/ozempic-adec4fd
- CounterForce Health. Do You Qualify for Ozempic/Mounjaro Coverage by UnitedHealthcare in Virginia? Decision Tree & Next Steps. https://www.counterforcehealth.org/post/do-you-qualify-for-ozempic-mounjaro-coverage-by-unitedhealthcare-in-virginia-decision-tree-next-steps
- CounterForce Health. How to Get Ozempic and Mounjaro Covered by Aetna CVS Health in Florida. https://www.counterforcehealth.org/post/how-to-get-ozempic-and-mounjaro-covered-by-aetna-cvs-health-in-florida-complete-prior-authorization-and-appeals-guide
- Pennsylvania Department of Human Services. GLP-1 Receptor Agonists Prior Authorization Guideline Revisions. January 2026. https://www.pa.gov/content/dam/copapwp-pagov/en/dhs/documents/about/dhs-information/documents/informationforadvocatesandstakeholders/maac/glp-1-receptor-agonists-maac-20260122.pdf
- Pennsylvania Department of Human Services. Medical Assistance Handbook: Prior Authorization of Pharmaceutical Services. March 2026. https://www.pa.gov/content/dam/copapwp-pagov/en/dhs/documents/docs/publications/documents/forms-and-pubs-omap/mab2026030201.pdf
- UnitedHealthcare. Prior Authorization/Notification — Plans with Weight Loss/Appetite Suppression Medication Coverage. Program 2026 P 1114-20. Effective May 1, 2026. https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Notification-Weight-Loss.pdf
- Prime Therapeutics / HCSC. GLP-1 Agonists Program Summary. May 2026. https://www.myprime.com/content/dam/prime/memberportal/forms/AuthorForms/HCSC/Program_Summaries/HCSC_GLP-1_Agonists_ProgSum.pdf
- CVS Caremark. Standard Clinical Criteria: Caremark Prior Authorization Forms. https://info.caremark.com/dig/pa-forms
- CMS. Medicare GLP-1 Bridge. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
- Congressional Research Service. Medicare Coverage of GLP-1 Drugs. IF12758. September 2024. https://www.congress.gov/crs-product/IF12758
- LDI University of Pennsylvania. Patients Face New Barriers for GLP-1 Drugs Like Wegovy and Ozempic. https://ldi.upenn.edu/our-work/research-updates/patients-face-new-barriers-for-glp-1-drugs-like-wegovy-and-ozempic
